Following a positive first half of 2024, the third quarter also went well for Krones. The company remained on a profitable growth path and, after the first nine months, confirms the group's financial targets for the full year 2024. The strong revenue growth continued from July to September 2024. At more than €1.3 billion, revenue increased by more than 13 per cent compared to the previous year. Production efficiency also improved due to the good availability of materials. In the prior year...

In the third quarter, the EBITDA before special items for the BASF Group rose by €77 million to €1.6 billion due to significantly higher contributions from the core businesses Chemicals, Materials (high-performance plastics), Industrial Solutions and Nutrition & Care. “The positive earnings momentum in our core businesses was already visible in the first half of 2024 and continued in the third quarter, driven by higher volumes and margins,” said Dr. Markus Kamieth, Chairman of the Board of...

Roche increased its sales by two percent to almost CHF 45 billion in the first nine months of 2024. Adjusted for currency effects, the pharmaceutical company achieved sales growth of six percent from January to September. Strong demand for modern medicines and diagnostics more than offset the expected decline in Covid-19 sales and the effects of erosion by biosimilars/generics. These include solutions for immunodiagnostics, pathology and molecular diagnostics. The appreciation of the Swiss franc...